Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco AI care platform automating chronic disease patient communication via SMS for health systems; extends care team capacity across oncology, cardiology, and behavioral health.
Memora Health is a San Francisco-based care enablement company that provides health systems with an AI platform to automate patient communication, care navigation, and chronic disease management between clinical visits. The platform uses conversational AI delivered via SMS to check in with patients, answer frequently asked questions, capture symptom reports, and escalate concerning findings to clinical staff — extending care team capacity without adding headcount. Memora targets chronic condition management programs including oncology, cardiovascular care, behavioral health, and pregnancy, where consistent patient monitoring between visits improves outcomes and reduces preventable hospitalizations. The platform integrates with EHR systems and enables care coordinators to manage larger patient panels by automating the routine communication that consumed their time. Founded in 2017, Memora raised over $80M from investors including General Catalyst, Andreessen Horowitz, and Kaiser Permanente Ventures. It competes with Luma Health and Welkin Health in the patient engagement and care management platform market.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.